The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2-Reference-Cited by-同舟云学术

The NFTI-QOL: A Disease-Specific Quality of Life Questionnaire for Neurofibromatosis 2

Published:2012-02-06 Issue:02 Volume:73 Page:104-111
ISSN:2193-6331
Container-title:Journal of Neurological Surgery Part B: Skull Base
language:en
Short-container-title:J Neurol Surg B

Author:

Hornigold Rachael¹²,Golding John³,Leschziner Guy¹,Obholzer Rupert¹²,Gleeson Michael¹²,Thomas Nick¹⁴,Walsh Daniel¹⁵,Saeed Shakeel¹⁵,Ferner Rosalie¹⁶

Affiliation:

1. National Specialist Commissioning Team Neurofibromatosis Unit, Department of Neurology, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

2. Department of ENT, Guy's and St. Thomas' NHS Foundation Trust, London, United Kingdom

3. University of Westminster, London, United Kingdom

4. King's College Hospital NHS Trust, London, United Kingdom

5. UCL Ear Institute and Royal National Throat, Nose, and Ear Hospital, London, United Kingdom

6. Department of Clinical Neuroscience, Institute of Psychiatry, King's College, London, United Kingdom

Publisher

Georg Thieme Verlag KG

Subject

Neurology (clinical)

Link

http://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0032-1301396.pdf

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of mental health on health-related quality of life in patients with NF2-related Schwannomatosis;Scientific Reports;2024-03-23

2. Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma;Journal of Neuro-Oncology;2024-02-19

3. Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series;Current Oncology;2023-03-20

4. The German version of the neurofibromatosis 2 impact on quality of life questionnaire correlates with severity of depression and physician-reported disease severity;Orphanet Journal of Rare Diseases;2023-01-06

5. Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2;Neuro-Oncology Advances;2023-01-01